

LANKA 20;

# WEEKLY EPIDEMIOLOGICAL REPORT

## A publication of the Epidemiology Unit Ministry of Health & Mass Media

231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 52 No. 37

06th - 12th Sep 2025

Strengthening Immunity among High-Risk Occupational groups: The Special Measles-Rubella (MR) Immunisation Campaign for Police, Tri-Forces and Civil Security Personnel - Part II

This is the second article of two in a series on "Strengthening Immunity among High-Risk Occupational groups: The Special Measles-Rubella (MR) Immunisation Campaign for Police, Tri-Forces and Civil Security Personnel"


This figure presents overall coverage for the ongoing Tri-Forces MR vaccination programme. Data were collected midway through the programme, which commenced in early July 2025, and represent the progress achieved after two months of implementation.

#### **Outcomes and Achievements**

The Tri Force MR Immunisation Campaign successfully vaccinated a significant proportion of targeted personnel, achieving 49% coverage after 2 months of implementation (halfway through implementation). The satisfactory acceptance rates midway through the programme, which commenced in early July 2025, reflect the effectiveness of pre-campaign awareness and advocacy efforts. Achieving high measles vaccination coverage in adults is more challenging than in children. Unlike children, who are reached through a well-organised routine immunisation program and school health system, adults lack a regular vaccination platform, making campaigns the primary strategy.

#### **Key outcomes include:**

- 1. Increased Immunity: The campaign reduced susceptibility to measles and rubella among police, Tri-Forces, and civil security personnel, protecting a workforce essential to national security and public safety.
- 2. Enhanced Awareness: Health education sessions improved understanding of vaccinepreventable diseases and reinforced positive health behaviours among personnel.





- 1. Strengthening Immunity among High-Risk Occupational groups: The Special Measles-Rubella (MR) Immunisation Campaign for Police, Tri-Forces and Civil Security Personnel-II
- 2. Summary of selected notifiable diseases reported (30th 05th Sep 2025)
- Surveillance of vaccine preventable diseases & AFP (30<sup>th</sup> 05<sup>th</sup> Sep 2025)

3

- 3. Strengthened Collaboration: The initiative strengthened partnerships between the health sector and security forces, establishing a model for future occupational immunisation programs.
- **4.** Evidence for Policy Planning: Data collected provide valuable insights for national immunisation planning, particularly regarding adult vaccination coverage in high-risk occupational groups.

#### **Challenges and Lessons Learned**

- Adult vaccination is particularly challenging: Unlike children, adults lack a routine vaccination platform and are harder to mobilise due to work commitments, mobility, and lower risk perception. Many are unaware of their vaccination status, requiring intensive awareness campaigns and flexible service delivery models.
- Operational constraints: Coordinating vaccination sessions around essential duties required flexibility.
- Vaccine hesitancy: A small proportion of personnel expressed concerns about side effects. Tailored counselling and transparent communication addressed these effectively.
- **Data management:** Maintaining accurate records in dynamic operational environments requires dedicated staff and robust systems.

Lessons learned highlight the importance of early engagement with leadership, targeted health education, and adaptive planning to ensure high coverage in occupationally critical groups.

The Tri Force MR Immunisation Campaign highlights a strategic, collaborative, and evidence-based approach to protecting highly important occupational groups from vaccine-preventable diseases. By strengthening immunity among police, Tri-Forces, and civil security personnel, the campaign protects individual health, ensures operational readiness, and contributes to national public health goals. This initiative serves as a model for similar campaigns, emphasising that disease prevention in critical workforce groups requires coordinated action, strong leadership, and sustained commitment.

To close the identified immunity gap among young adults, relying solely on catch-up campaigns is not feasible, as these campaigns are resource-intensive and difficult to sustain. Achieving high coverage through adult catch-up campaigns alone is challenging due to work commitments, mobility, and the absence of routine vaccination platforms for adults. Therefore, making MR vaccines routinely available at MOH offices for targeted adult age groups offers a more efficient and sus-

tainable approach to closing these immunity gaps. In addition, systematic verification of MR vaccination status during recruitment or pre-deployment medical assessments can help identify susceptible individuals. When combined with targeted health education, risk communication, and accessible vaccination services, these strategies can effectively close MR immunity gaps and ensure sustained protection among high-risk occupational groups, safeguarding both the workforce and the wider community.

#### Compiled by:

Dr. Athula Liyanapathirana (Consultant Epidemiologist)
Dr. Aruni Hathamuna (Associate Specialist Community
Physician)
Maj (Dr) Pathum Pinnaduwa (Registrar, Health Informatics)
Epidemiology Unit
Ministry of Health

#### References:

- CDC. (2024). Measles Vaccine Recommendations. Measles (Rubeola). <a href="https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html">https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html</a>
- 2. Immunization Handbook Health New Zealand | Te Whatu Ora. (n.d.). Www.tewhatuora.govt.nz. <a href="https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook#pdf-download">https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook#pdf-download</a>
- WHO. (2017). Measles vaccines: WHO position paper

   April 2017. Www.who.int.
   <a href="https://www.who.int/publications/i/item/who-wer9217">https://www.who.int/publications/i/item/who-wer9217</a>
   -205-227
- 4. WHO recommendations for routine immunization summary tables. (2024). Who.int.

  <a href="https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables?">https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables?</a>

  utm source=chatgpt.com

Table 1: Selected notifiable diseases reported by Medical Officers of Health 30th - 05th Sep 2025 (36th Week)

Tab	le 1	: 50	elec	ted	noti	itiab	ole c	lisea	ases	s rep	oort	ed k	у№	edi	cal	Offic	cers	ot I	неа	lth	30 <sup>tn</sup>	-05	in S	ep 2	025	(36	om V	Veek	()
	*	100	100	97	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	90	100	100	100	100	100	66	
WRCD		100	93	100	02	92	92	92	100	100	98	75	100	100	100	100	100	100	100	92	87	100	100	100	82	82	100	94	
\$	<u>*</u>		841	400	462	110	201	363	107	126	156	38	39	44	25	102	44	85	253	136	233	99	223	110	290	200	86	2	
sisolr	В	1425	8	4	4	+	7	36	7	7	#	( )		1		7	,	~	25	7	23		22	<del>`</del>	56	7	O,	6177	
Tuberculosis	<b>4</b>	4	28	73	∞	7	4	7	0	7	2	7	0	7	_	0	0	0	∞	0	0	0	0	က	က	7	4	162	
	1	က	36	7	29	215	0	က	223	11	0	7	2	16	က	~	22	∞	447	26	547	338	48	165	166	24	0	2436	
Leishmania-	В	0	_	0	0	9	0	0	7	0	0	0	0	0	0	0	0	_	12	_	18	œ	<del>-</del>	œ	<del>-</del>	_	0	65 2	
Lei	⋖	54	29	37	20	œ	29	124	20	35	22	0	13	17	2	27	42	12	128	74	52	21	62	38	95	96	45	02	
Meningitis	В		_			_						_																1202	
Men	⋖	10	3	9	3 0	0	7	_	0 6	0 2	1 0	0	3 0	0	0 0	0 9	2 0	0 0	2	_	1	1 2	9	0	9 2	9 (	3	3 27	
xodu	В	425	633	658	413	104	222	581	249	310	261	,	18	41	30	155	172	100	652	121	265	151	309	142	349	099	163	7188	
Chickenpox	4	4	16	13	13	5	00	23	က	12	2	0	0	7	0	2	5	0	13	~	10	~	2	~	7	17	7	177	
Rabiies	В	0	0	0	0	0	0	~	0	0	2	0	0	0	0	0	~	~	~	~	_	0	0	0	~	0	~	10	
H. Ra	⋖	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	_	0	0	_	0	0	0	0	0	0	7	
Viral Hep.	В	4	15	2	7	တ	5	00	<b>—</b>	16	က	_	_	0	0	22	O	Ω.	7	2	12	21	54	46	13	17	5	312	
Viral	⋖	5 4	0 (	0	0 8	5 0	3 2	0	0 8	e -	0 ,	0	0 1	0	0 0	0	_	0	0 1	0	0 8	_	0	3	0 ,	1 2	_	16	
S. T.	В	4,	10	က	43	4,	48	99	28	14	407	7	14	10	10	2	8	6	24	33	23	_	25	33	27	14	_	869	
Typhus F	⋖	0	0	0	<b>←</b>	~	0	~	0	0	0	0	0	0	0	0	0	0	0	0	<b>←</b>	0	0	0	0	~	0	.c	
rosis		330	573	471	225	188	134	009	297	364	128	64	26	75	53	98	188	119	553	211	309	233	230	445	1134	588	87	7723	
Leptospirosis	В	7	10	23	10	က	7	œ	<del></del>	4	0	0	<b>—</b>	~	0	7	4	0	3	4	က	7	0	က	12	17	0	143	
	⋖	34	136	20	36	99	62	29	2	12	43	2	က	38	23	157	<del>0</del>	74	49	1	34	10	7	4	22	34	21	1046	
F. Poisoning	В	0	. ω	2	0	0	3	<b>←</b>	0	0	0	0	<b>←</b>	0	0	·	0	0	0	0	<del>-</del>	0	0	0	0	2	0	22 10	
	⋖	12	က	2	7	<b>—</b>	9	7	0	<b>←</b>	16	4	0	-	<del></del>	2	0	7	2	0	က	<b>←</b>	8	0	4	6	0	103	
En. Fever	В	<b>←</b>	0	0	0	0	<del>-</del>	0	0	0	<u></u>	0	0	0	0	0	0	<b>←</b>	<del>-</del>	0	0	0	0	0	0	0	0	5	
	A	7	25	9	က	7	9	4	2	7	2	-	0	0	0	4	<b>=</b>	4	15	က	9	9	10	က	œ	13	9	166	
Encephalitis	В	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	<del>-</del>	0	0	0	0	<u>-</u>	
	⋖	24	39	31	42	23	69	40	34	4	74	4	2	တ	2	111	41	37	41	24	29	15	26	22	06	49	32	940	
Dysentery	В	0	_	0	0	က	_	<b>—</b>	0	0	0	0	0	0	0	<u>←</u>	_	0	0	0	0	0	0	2	<del>-</del>	0	_		
	⋖		31			955	260		710		938	74	132	20	49		200	902		510	452	277	631	029			320	89 12	
Dengue Fever	В	8607	5631	1868	3407	Ó	2	1589	7	1252			-			1548	2	ō	1300	5	4	2	9	9	3863	1174	3	37389	
Dengu	4	103	58	34	87	31	7	33	6	16	22	2	2	0	0	∞	2	က	∞	5	2	4	00	က	29	19	4	529	
							Eliya		ota			Ë		_	3	ro O		alee	ala		apura	има		ala	g		_	Α¥	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	
꿉		ၓ	ගී	조	조	Ĕ	ž	ඊ	岩	ğ	Ja	茎	ğ	>	ž	g	Ā	Ē	조	7	¥	A.	Ba	ž	Ra	조	Χ	Ŋ	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.Ik). T=Timeliness refers to returns received on or before 05th Sep, 2025 Total number of reporting units 360 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

30th - 05th Sep 2025 (36th Week)

Disease	No. o	f Case	s by F	Provinc	e			Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date			
	W	С	S	N	Е	NW	NC	U	Sab	week in 2025	week in 2024	2025	2024	in 2025 & 2024	
AFP*	00	00	00	00	00	00	00	00	01	01	02	44	50	-12%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	00	00	01	00	00	02	00	01	02	06	08	176	204	-13.7 %	
Measles	00	00	00	00	00	00	00	00	00	00	1	01	284	-99.6%	
Rubella	00	00	00	00	00	00	00	00	00	00	00	04	02	-100%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	05	0 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Encephalitis	00	00	00	00	00	00	00	00	00	00	00	04	06	33.3 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	17	41	-58.5 %	

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

### ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10